Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts

Respiratory Research

Volumn 18, Issue 1, 2017, Pages

  Lam, Sze Kwan ^a   Li, Yuan Yuan ^a   Xu, Shi ^a   Leung, Leanne Lee ^a   U, Kin Pong ^b   Zheng, Yan Fang ^c   Cheng, Paul Ning Man ^b   Ho, James Chung Man ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Bio Cancer Treatment International Limited   (Hong Kong)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; BCT 100; Cell cycle arrest; Mesothelioma; Pegylated arginase; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; ARGININOSUCCINATE SYNTHASE; BCT 100; CASPASE 3; CISPLATIN; CRYSTAL VIOLET; CYCLIN A2; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN E1; CYCLIN H; CYCLINE; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORNITHINE CARBAMOYLTRANSFERASE; PEMETREXED; PROTEIN BCL 2; UNCLASSIFIED DRUG; ARGINASE; MACROGOL DERIVATIVE;

AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MESOTHELIOMA CELL LINE; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; STAINING; SURVIVAL; TUMOR XENOGRAFT; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; LUNG TUMOR; MESOTHELIOMA; NUDE MOUSE; PATHOLOGY; PLEURA TUMOR; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARGINASE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; PLEURAL NEOPLASMS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 85018992572     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-017-0564-3     Document Type: Article

References (22)

1. Borasio P, Berruti A, Bille A, Lausi P, Levra MG, Giardino R, Ardissone F. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg. 2008;33:307-13.
2. Abakay A, Abakay O, Tanrikulu AC, Sezgi C, Sen H, Kaya H, Kucukoner M, Kaplan MA, Celik Y, Senyigit A. Effects of treatment regimens on survival in patients with malignant pleural mesothelioma. Eur Rev Med Pharmacol Sci. 2013;17:19-24.
3. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010;126:2762-72.
4. Chow AK, Ng L, Sing Li H, Cheng CW, Lam CS, Yau TC, Cheng PN, Fan ST, Poon RT, Pang RW. Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma. Curr Cancer Drug Targets. 2012;12:1233-43.
5. Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs. 2006;15:815-22.
6. Yau T, Cheng PN, Chan P, Chen L, Yuen J, Pang R, Fan ST, Wheatley DN, Poon RT. Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015;33:496-504.
7. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leung YC. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007;67:309-17.
8. Tanios R, Bekdash A, Kassab E, Stone E, Georgiou G, Frankel AE, Abi-Habib RJ. Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells. Leuk Res. 2013;37:1565-71.
9. Lam TL, Wong GK, Chow HY, Chong HC, Chow TL, Kwok SY, Cheng PN, Wheatley DN, Lo WH, Leung YC. Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. Pigment Cell Melanoma Res. 2011;24:366-76.
10. Lam TL, Wong GK, Chong HC, Cheng PN, Choi SC, Chow TL, Kwok SY, Poon RT, Wheatley DN, Lo WH, Leung YC. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett. 2009;277:91-100.
11. Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer JF, J. LM, Bomalaski JS, A. FD, Hackshaw A: Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma. J Clin Oncol 2014, 32:suppl; abstr 7507.
12. Li YY, Lam SK, Mak JC, Zheng CY, Ho JC. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer. 2013;81:354-61.
13. Kousparou CA, Yiacoumi E, Deonarain MP, Epenetos AA. Generation of a selectively cytotoxic fusion protein against p53 mutated cancers. BMC Cancer. 2012;12:338.
14. Lam SK, Li YY, Zheng CY, Ho JC. Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma. Int J Oncol. 2015;46:113-22.
15. Qiu F, Huang J, Sui M. Targeting arginine metabolism pathway to treat arginine-dependent cancers. Cancer Lett. 2015;364:1-7.
16. Ranganath P, Einhorn L, Albany C. Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy. Biomed Res Int. 2015;2015:943618.
17. Glezerman IG, Pietanza MC, Miller V, Seshan SV. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis. 2011;58:817-20.
18. Galateau-Salle F, Churg A, Roggli V, Travis WD, World Health Organization Committee for Tumors of the P. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. J Thorac Oncol. 2016;11:142-54.
19. Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, Loke J, Pratt G, U KP, Lo A, et al: Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood 2015, 125:2386-2396.
20. Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11:1566-72.
21. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659-61.
22. Yau T, Yao TJ, Chan P, Ng K, Fan ST, Poon RT. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer. 2008;113:2742-51.